What’s new

• Trident Texofab forfeited 9,11,479 fully convertible warrants from its December 2024 preferential issue.
• The upfront amount of ₹1.59 crore is retained; no equity shares were issued.
• The cash gain is about 2.9% of market cap, material for a ₹59 crore nano-cap.

Why it matters

For a company with trailing PAT down 494% and a P/E of 83.3, a one-time cash injection of ₹1.59 crore will meaningfully lift book value and earnings this quarter. But it's non-recurring — the operating business remains under pressure.

What we’re watching

• Whether the company uses the cash to pare debt (D/E 0.56) or fund working capital.
• Next quarterly results for signs of core business recovery.
• Any further fund-raise plans after this warrant lapse.

The full read

Trident Texofab just pocketed ₹1.59 crore in free cash. The money comes from 9,11,479 fully convertible warrants issued in December 2024 that holders chose not to exercise. The ₹70-a-share warrants required only 25% upfront, yet not a single warrant was converted by the June 22 deadline. All 9.11 lakh lapsed. For a ₹59 crore nano-cap with trailing PAT down 494% and a P/E of 83.3, that ₹1.59 crore is a material windfall, roughly 2.9% of market cap. The equity base stays unchanged, so book value and earnings get a one-time lift. But the operating business, with revenue down 12.1% and debt at 0.56 times equity, remains under stress. This is a pleasant surprise, not a turnaround.

Primary source: BSE · NSE